What clinicians must know about diabetic dyslipidemia

Professor Martin Clodi shares his insights what clinicians must know about diabetic dyslipidemia at the 4th World Congress of Lipidology in Vienna, Austria.

How to treat elevated Lp(a)

Professor Karam Kostner shares his insights how to treat elevated Lp(a) at the 4th World Congress of Lipidology in Vienna, Austria?

The lower the better: never mind future drugs, use what you have available to fullest extent and lower cardiovascular risk aggressively

Professor Peter Toth shares his insights on how to lower cardiovascular risk at the 4th World Congress of Lipidology in Vienna, Austria.

How to treat elevated TG in other high risk patients

Professor Thomas Stulnig shares his insights on how to treat elevated TG in other high risk patients at the 4th World Congress of Lipidology in Vienna, Austria.

What will change in the lipid lowering landscape in the next 5 years?

Professor Maciej Banach shares his insights what will change in the lipid lowering landscape in the next 5 years at the 4th World Congress of Lipidology in Vienna, Austria.

Newborn Screening for Atherosclerosis Risk?

Professor Caroline Bachmeier shares her insights on the rationale of small children and newborn screening for atherosclerosis at the 4th World Congress of Lipidology in Vienna, Austria.

How to implement LDL guidelines?

Professor Gerald Watts shares his insights how to implement LDL guidelines at the 4th World Congress of Lipidology in Vienna, Austria.

LDL lowering in 2025: Optimal approach

Professor Dereck Connolly shares his insights on LDL lowering in 2025 at the 4th World Congress of Lipidology in Vienna, Austria.

Diabetic Dyslipidemia: Beyond LDL – Atherogenic Lipoproteins in Focus

Professor Gersina Rega Kaun shares her insights on lipid lowering in diabetics at the 4th World Congress of Lipidology in Vienna, Austria.

Targeting CV risk factors with GLP-1 RAs in people with obesity

Professor Michael Lincoff shares with us a discussion occurred during the EASD 2022 meeting, this was focusing on the modification of cardiovascular risk in patients with obesity with the GLP-1 receptor agonists.

Once weekly insulin: The ONWARDS 2 study

Professor Tina Vilsbøll chaired a very interesting session looking into once weekly insulin.

Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

We asked Professor Silvio Inzucchi about the key messages of the DELIVER study, he talked about this topic at the recent EASD 2022.

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm.

Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg

Domenica Rubino, Director of Washington Center for Weight Management & Research at Arlington, Virginia, USA, held a very interesting lecture about weight control at the recent EASD 2022 Congress.

Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising

Continuous glucose monitoring gives us the opportunity to better analyze diabetes. The new insights help us to improve the therapy of our patients in the active daily life and even during physical exercise. Dr. Othmar Moser held two lectures about this topic the recent EASD 2022 congress.

Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity

Professor Ambarish Pandey presented the results a randomised clinical trial about the effect of liraglutide on muscle fat infiltration in overweight or obesity adults at the recent EASD 2022 Congress. We asked him about the result.

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

50 years of clinical research in diabetes

50 years in treatment of diabetes complications

50 years of diabetes treatment

75 years with diabetes – a patient’s perspective